Art. -Nr.: HY-16141

Cilengitide

Name: Cilengitide
Brand: MedChemExpress
SKU: HY-16141
Price: 132.00 USD
Availability: InStock
Rating: 5 (75 reviews)

(Synonyms: EMD 121974)

75 Cited Publications

Kundenbewertung

Based on 75 publication(s) in Google Scholar

Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC₅₀ values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.91%
CAS. Nr.: 188968-51-6
Formel: C₂₇H₄₀N₈O₇
Molecular Weight:588.66

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 1 year , -20°C, 6 months

Cilengitide Chemical Structure

CAS. Nr.: 188968-51-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (75)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]^[2]^[3]

αvβ3

0.61 nM (IC₅₀)

αvβ5

8.4 nM (IC₅₀)

α5β1

14.9 nM (IC₅₀)

αIIbβ3

5400 nM (IC₅₀)

αvβ6

2050 nM (IC₅₀)

αvβ8

2350 nM (IC₅₀)

Alle Integrin Isoform-spezifische Produkte anzeigen :

Alle TGF-β Receptor Isoform-spezifische Produkte anzeigen :

Alle STAT Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle mTOR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	0.54 nM Compound: Cilengitide	Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta3 (Gly27 to Asp718 residues) expressed in CHO cells by ELISA based solid phase binding assay Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta3 (Gly27 to Asp718 residues) expressed in CHO cells by ELISA based solid phase binding assay	[PMID: 32094009]
CHO	IC₅₀	15.4 nM Compound: Cilengitide	Inhibition of fibronectin binding to recombinant human integrin alpha5 (Phe42 to Tyr995 residues) beta1 (Gln21 to Asp728 residues) expressed in CHO cells by ELISA based solid phase binding assay Inhibition of fibronectin binding to recombinant human integrin alpha5 (Phe42 to Tyr995 residues) beta1 (Gln21 to Asp728 residues) expressed in CHO cells by ELISA based solid phase binding assay	[PMID: 32094009]
CHO	IC₅₀	8 nM Compound: Cilengitide	Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta5 (Gly24 to Asn719 residues) expressed in CHO cells by ELISA based solid phase binding assay Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta5 (Gly24 to Asn719 residues) expressed in CHO cells by ELISA based solid phase binding assay	[PMID: 32094009]
HEK-293T	IC₅₀	0.51 nM Compound: c(RGDfV)	Binding affinity to soluble truncated human recombinant Fc-tagged alphaVbeta3 and integrins were expressed in HEK293T cells after 2 hrs by competition ELISA-like assay Binding affinity to soluble truncated human recombinant Fc-tagged alphaVbeta3 and integrins were expressed in HEK293T cells after 2 hrs by competition ELISA-like assay	[PMID: 24095096]
M21	IC₅₀	0.4 nM Compound: c[RGDf(Me)V]; Cilengitide	Binding affinity to integrin alphav/beta3 heterodimer in human M21 cells assessed as inhibition of integrin-mediated human M21 cell adhesion to vitronectin after 1 hr in presence of MnCl2 Binding affinity to integrin alphav/beta3 heterodimer in human M21 cells assessed as inhibition of integrin-mediated human M21 cell adhesion to vitronectin after 1 hr in presence of MnCl2	[PMID: 26753814]
M21	IC₅₀	0.4 μM Compound: 2	Inhibition of integrin alpha-v/beta-3 mediated M21 cell adhesion to vitronectin with monoclonal antibody P1F6 Inhibition of integrin alpha-v/beta-3 mediated M21 cell adhesion to vitronectin with monoclonal antibody P1F6	[PMID: 11855984]

In Vitro

Cilengitide (1-1000 µg/mL; 24-72 h) inhibits the viability of B16 and A375 cells in a time- and dose-dependent manner^[2].
Cilengitide (5-10 µg/mL; two weeks) inhibits colony formation of B16 and A375 melanoma cells^[2].
Cilengitide (5-10 µg/mL; 12 h) induces apoptosis in B16 and A375 melanoma cells^[2].
Cilengitide (5 µg/mL; 12 h) alters the transcriptome of B16 melanoma cells, regulates genes and pathways involved in cell growth, apoptosis and integrin signaling pathways, including reducing the phosphorylation levels of AKT and mTOR^[2].
Immunofluorescence staining shows that Cilengitide (5 µg/mL; 12 h) reduces PD-L1 expression levels in B16 and A375 melanoma cells, decreases the proportion of PD-L1-positive B16 and A375 melanoma cells, and lowers the positive rate from 38.1-41.1% to 17.9-18.2% after 12 hours of incubation^[2].
Cilengitide (5-20 µg/mL; 12 h) reduces the expression level of PD-L1 and the phosphorylation level of STAT3^Tyr705 in B16 and A375 melanoma cells, without altering the expression level of total STAT3 protein^[2].
Cilengitide (5 µg/mL; 12 h) downregulates PD-L1 expression in B16 and A375 melanoma cells by reducing the phosphorylation level of STAT3, while IL-6-induced STAT3 activation reverses this PD-L1 downregulation^[2].
Cilengitide (6.4 nM-20 μM; 1 h) exhibits the strongest inhibitory effect on the binding of human αvβ3 integrin to vitronectin (IC₅₀ = 0.61 nM), while it also shows high affinity for αvβ5 (IC₅₀ = 8.4 nM) and α5β1 (IC₅₀ = 14.9 nM). In contrast, its affinity for αvβ6, αvβ8 and αIIbβ3 integrins is significantly reduced^[1].
Cilengitide (2 μM) inhibits integrin-mediated adhesion of human umbilical vein endothelial cells to vitronectin, with an IC₅₀ of 2 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

B16, A375 melanoma cell lines
Concentration:

0, 1, 10, 100, 1000 µg/mL
Incubation Time:

24 h; 48 h; 72 h
Result:

Inhibited B16 and A375 cell growth in a time- and dose-dependent manner.
Reduced B16 cell viability with IC₅₀ values of 12 µg/mL (24 h), 10 µg/mL (48 h), 8 µg/mL (72 h).
Reduced A375 cell viability with IC₅₀ values of 4 µg/mL (24 h), 1.5 µg/mL (48 h), 0.5 µg/mL (72 h).

Apoptosis Analysis^[2]

Cell Line:

B16, A375 melanoma cell lines
Concentration:

0, 5, 10 µg/mL
Incubation Time:

12 h
Result:

Increased B16 cell apoptosis rate from ~7% (untreated) to ~15.27% (5 µg/mL) and ~21.71% (10 µg/mL).
Increased A375 cell apoptosis rate from ~3% (untreated) to ~14.89% (5 µg/mL) and ~36.6% (10 µg/mL).

Immunofluorescence^[2]

Cell Line:

B16, A375 melanoma cell lines
Concentration:

5 µg/mL
Incubation Time:

12 h
Result:

Downregulated PD-L1 expression in B16 and A375 cells, as shown by reduced fluorescent signal compared to untreated controls.

Western Blot Analysis^[2]

Cell Line:

B16, A375 melanoma cell lines
Concentration:

0, 5, 10, 20 µg/mL
Incubation Time:

12 h
Result:

Reduced PD-L1 protein levels by ~50% (5 µg/mL), ~60% (10 µg/mL), and ~70% (20 µg/mL) in both cell lines.
Reduced STAT3 (Tyr705) phosphorylation by ~30% (5 µg/mL), ~40% (10 µg/mL), and ~60% (20 µg/mL) in both cell lines.
Caused no significant change in total STAT3 protein levels across groups.

Western Blot Analysis^[2]

Cell Line:

B16, A375 melanoma cell lines
Concentration:

5 µg/mL (alone or combined with 20 ng/mL IL-6)
Incubation Time:

12 h
Result:

Reduced PD-L1 expression and STAT3 phosphorylation when used alone.
Reversed IL-6-induced increases in STAT3 phosphorylation and PD-L1 expression, restoring PD-L1 levels and STAT3 phosphorylation to near-control levels in co-treatment groups.

In Vivo

Cilengitide (50 mg/kg; i.p.; once daily; for 7 consecutive days) downregulates PD-L1 expression in subcutaneous melanoma tumors of mice, exhibits moderate anti-tumor activity by enhancing CD8⁺ T cell-mediated immune responses, and reduces the bioluminescent signal of luciferase-expressing subcutaneous melanoma in mice^[2].
Cilengitide (10-250 μg; intraperitoneal injection; three times per week) inhibits the tumor growth of M21-L melanoma in nude mice in a dose-dependent manner^[3].
Cilengitide (100 μg; i.p.) results in 100% survival rate and nearly complete tumor clearance in nude mice bearing medulloblastoma and glioblastoma xenografts at day 28^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6^[2]
Dosage:

50 mg/kg
Administration:

i.p.; daily; 7 days
Result:

Reduced PD-L1 protein expression in subcutaneous B16 melanoma tumors.
Showed moderate antitumor activity, with smaller tumor volumes compared to control at day 20 post-implantation.
Increased intratumoral CD8+ T cell infiltration and tumor granzyme B and IFN-γ levels relative to control.
Reduced bioluminescent tumor signal strength relative to control at day 20 post-implantation.
When combined with anti-PD1 therapy, caused significantly weaker tumor signal than with either monotherapy.

Animal Model:

Nude mice^[3]
Dosage:

10 μg; 50 μg; 250 μg
Administration:

i.p.; three times per week
Result:

Reduced tumor volume by 55% and tumor weight by 23%.
Reduced tumor volume by 75% and tumor weight by 38%.
Reduced tumor volume by 89% and tumor weight by 61%.

Animal Model:

Nude mice^[3]
Dosage:

100 μg
Administration:

i.p.
Result:

Resulted in 100% survival of mice at 28 days.
Induced almost complete histological disappearance of tumors.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 188968-51-6
Appearance Solid
Molecular Weight 588.66
Formel C₂₇H₄₀N₈O₇
Color White to light yellow
SMILES

O=C(NCC(N[C@H](C(N[C@H](CC1=CC=CC=C1)C(N([C@H]2C(C)C)C)=O)=O)CC(O)=O)=O)[C@H](CCCNC(N)=N)NC2=O
Synonyms

EMD 121974
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (75)

All In Vivo Efficacy StudyCell Proliferation/Viability AssayIFIHCWB

Sort by:

Journal Impact Factor

Cancer Cell

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. [Abstract]

2021 Nov 8;39(11):1531-1547.e10. PMID: 34624218
Cell

Type V Collagen in Scar Tissue Regulates the Size of Scar after Heart Injury. [Abstract]

2020 Aug 6;182(3):545-562.e23. PMID: 32621799
Nat Mater

Peptide codes for organ-selective mRNA delivery. [Abstract]

2025 Sep 1. PMID: 40890497
Nat Cell Biol

Crosstalk with lung epithelial cells regulates Sfrp2-mediated latency in breast cancer dissemination. [Abstract]

2020 Mar;22(3):289-296. PMID: 32094692
J Clin Invest

Excessive collagen type VII mediates pleural fibrosis via increasing extracellular matrix stiffness. [Abstract]

2025 Oct 16:e188822. PMID: 41100460
Adv Sci (Weinh)

Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface. [Abstract]

2025 Oct 30:e01602. PMID: 41168993
Adv Sci (Weinh)

Drug Screening of Primary Human Endometriotic Cells Based on Micro-Encapsulating Microfluidic Chip. [Abstract]

2025 May;12(20):e2504647. PMID: 40289897
Cell Rep Med

MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1. [Abstract]

2025 Feb 18;6(2):101922. PMID: 39842432
Sci Adv

Integrin inhibition facilitates fibrocartilaginous transformation in connective tissue in osteoarthritis. [Abstract]

2026 Jan 2;12(1):eady4112. PMID: 41481715
Sci Adv

Dynamic adaptive coassembled sericin protein orchestrating stem cell development for nucleus pulposus regeneration. [Abstract]

2026 Jan 2;12(1):eadx2768. PMID: 41477862
Chem Eng J

2025 Dec 20.
Cell Death Dis

Matrix stiffness maintains bladder cancer stemness via integrin-nuclear skeleton axis. [Abstract]

2025 Dec 12;16(1):887. PMID: 41387479
Cell Death Dis

Laminins in tumor-derived exosomes upregulated by ETS1 reprogram omental macrophages to promote omental metastasis of ovarian cancer. [Abstract]

2022 Dec 7;13(12):1028. PMID: 36477408
Engineering

8 October 2020.
Int J Biol Sci

Integrative Single-Cell and Spatial Transcriptomics Analysis Reveals ECM-remodeling Cancer-associated Fibroblast-Derived POSTN as a Key Mediator in Pancreatic Ductal Adenocarcinoma Progression. [Abstract]

2025 May 27;21(8):3573-3596. PMID: 40520021
J Immunother Cancer

Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma. [Abstract]

2020 Mar;8(1):e000111. PMID: 32152220
J Transl Med

Integrin ανβ5 in vitro inhibition limits pro-fibrotic response in cardiac fibroblasts of spontaneously hypertensive rats. [Abstract]

2018 Dec 12;16(1):352. PMID: 30541573

Cilengitide purchased from MedChemExpress. Usage Cited in: J Transl Med. 2018 Dec 12;16(1):352. [Abstract]

Representative images of immunofluorescence performed for α-SMA on WKY- and SHR-CF in the treatment of TGF-β1, cilengitide or both.

Cilengitide purchased from MedChemExpress. Usage Cited in: J Transl Med. 2018 Dec 12;16(1):352. [Abstract]

Representative Western blot images of ανβ5 and collagen I protein expression in WKY- and SHR-CF cultured on substrates with two different stiffness (high and low) and contemporary treated with 5 ng/ml TGF-β1, TGF-β1 + 0.5 μM cilengitide, or cilengitide.
Oncogene

Fibroblast Activation Protein (FAP)+ cancer-associated fibroblasts induce macrophage M2-like polarization via the Fibronectin 1-Integrin α5β1 axis in breast cancer. [Abstract]

2025 Jul;44(28):2396-2412. PMID: 40263422
Cell Mol Gastroenterol Hepatol

MFAP4 Deficiency Attenuates Liver Fibrosis by Regulating Hepatic Stellate Cell Fate through Inhibition of the FAK/PI3K/NFκB Signaling Pathway. [Abstract]

2025;19(10):101548. PMID: 40449846

Cilengitide purchased from MedChemExpress. Usage Cited in: Cell Mol Gastroenterol Hepatol. 2025;19(10):101548. [Abstract]

The fibrotic and apoptotic phenotypes induced by rMFAP4 incubation in LX-2 cells and by MFAP4 overexpression in LX-2 cells can be partially reversed by the integrin αvβ3 inhibitors Cilengitide TFA (1 μM).

Cilengitide purchased from MedChemExpress. Usage Cited in: Cell Mol Gastroenterol Hepatol. 2025;19(10):101548. [Abstract]

The integrin αvβ3 inhibitor Cilengitide TFA (1 μM) partially reverses the activation of the FAK/PI3K/NFκB signaling pathway induced by rMFAP4 incubation or OE-MFAP4 in LX-2 cells.
Free Radic Biol Med

Crucial roles of asprosin in cisplatin-induced ferroptosis and acute kidney injury. [Abstract]

2024 Dec 9:227:296-311. PMID: 39653130
Clin Transl Med

Targeting integrin αvβ3 with indomethacin inhibits patient-derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma. [Abstract]

2021 Oct;11(10):e548. PMID: 34709754
Br J Cancer

Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT. [Abstract]

2023 Mar;128(7):1344-1359. PMID: 36717670
Cell Rep

2026 Jul 28;45(7):117650. PMID: 42400907

Cilengitide purchased from MedChemExpress. Usage Cited in: Cell Rep. 2026 Jul 28;45(7):117650.

Mice inoculated with control cells (shNeg) were taken down at day 15, and those receiving Cilengitide TFA alone were taken a week later. Probability of survival using Kaplan-Meier survival analysis.

Cilengitide purchased from MedChemExpress. Usage Cited in: Cell Rep. 2026 Jul 28;45(7):117650.

Mice inoculated with control cells (shNeg) were taken down at day 15, and those receiving Cilengitide TFA alone were taken a week later. IVIS quantification of luminescent counts over time highlighting takedown (5e5 luminescence counts) and low tumor burden (1e4 luminescence counts) windows.

Cilengitide purchased from MedChemExpress. Usage Cited in: Cell Rep. 2026 Jul 28;45(7):117650.

Inhibition of RelB in mice that received chemotherapy and cilengitide led to the greatest number of days with low luminescent counts.
Cell Rep

Hepatic ER stress suppresses adipose browning through ATF4-CIRP-ANGPTL3 cascade. [Abstract]

2022 Sep 27;40(13):111422. PMID: 36170814
Environ Pollut

Low-dose graphene oxide promotes tumor cells proliferation by activating PI3K-AKT-mTOR signaling via cellular membrane protein integrin αV. [Abstract]

2023 Aug 1:330:121817. PMID: 37182579
Blood Rev

Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatment. [Abstract]

2023 May:59:101038. PMID: 36581513
Front Immunol

Adaptive Regulation of Osteopontin Production by Dendritic Cells Through the Bidirectional Interaction With Mesenchymal Stromal Cells. [Abstract]

2018 Jun 1:9:1207. PMID: 29910810
Mol Cancer Ther

Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. [Abstract]

2022 Sep 6;21(9):1485-1496. PMID: 35793463
Biochem Pharmacol

Irisin alleviates steroid-induced vascular dysfunction by regulating the αVβ5-c-Abl-Caveolin-1 signaling pathway. [Abstract]

2025 Jun:236:116870. PMID: 40086515
J Chem Inf Model

Molecular View on the i RGD Peptide Binding Mechanism: Implications for Integrin Activity and Selectivity Profiles. [Abstract]

2023 Oct 23;63(20):6302-6315. PMID: 37788340
Oncoimmunology

Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization. [Abstract]

2025 Dec;14(1):2508057. PMID: 40401531
J Cell Biol

Reticular adhesions are assembled at flat clathrin lattices and opposed by active integrin α5β1. [Abstract]

2023 Aug 7;222(8):e202303107. PMID: 37233325
Colloids Surf B Biointerfaces

Guiding macrophage temporal evolution via integrin targeting on peptide-functionalized titanium surfaces to optimize the host response. [Abstract]

2026 Sep:265:115699. PMID: 41967441
Commun Biol

Abnormal cytoskeletal remodeling but normal neuronal excitability in a mouse model of the recurrent developmental and epileptic encephalopathy-susceptibility KCNB1-p.R312H variant. [Abstract]

2024 Dec 30;7(1):1713. PMID: 39738805
Respir Res

The MFGE8/integrin β3 axis mitigates experimental neutrophilic asthma by suppressing NLRP3-Caspase-1 pathway-mediated NETosis. [Abstract]

2025 Jul 2;26(1):229. PMID: 40605028
Int Immunopharmacol

Irisin attenuates acute glaucoma-induced neuroinflammation by activating microglia-integrin αVβ5/AMPK and promoting autophagy. [Abstract]

2024 Sep 10:138:112545. PMID: 38955026
Stem Cell Reports

Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells. [Abstract]

2017 Dec 12;9(6):1948-1960. PMID: 29198824
Front Pharmacol

Antagonizing αvβ3 Integrin Improves Ischemia-Mediated Vascular Normalization and Blood Perfusion by Altering Macrophages. [Abstract]

2021 Feb 24:12:585778. PMID: 33716733
Am J Physiol Cell Physiol

Expression of CTGF/CCN2 in response to LPA is stimulated by fibrotic extracellular matrix via the integrin/FAK axis. [Abstract]

2018 Apr 1;314(4):C415-C427. PMID: 29351412

Cilengitide purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2018 Apr 1;314(4):C415-C427. [Abstract]

C2C12 cells are pre-incubated with different concentrations of Cilengitide prior to LPA 20 μg/mL addition and incubation for 3 hours. CTGF levels are analyzed.
Biochim Biophys Acta Mol Basis Dis

CCL2/CCR2 axis promotes perineural invasion of salivary adenoid cystic carcinoma via ITGβ5-mediated nerve-tumor interaction. [Abstract]

2025 Jan;1871(1):167484. PMID: 39222826
Obesity

Immunological blockade of adipocyte inflammation caused by increased matrix metalloproteinase-cleaved osteopontin in obesity. [Abstract]

2015 Apr;23(4):779-85. PMID: 25776538
Cancers (Basel)

Sandwich Culture Platforms to Investigate the Roles of Stiffness Gradients and Cell-Matrix Adhesions in Cancer Cell Migration. [Abstract]

2023 Mar 12;15(6):1729. PMID: 36980615
Mol Cell Biochem

Irisin protects against atherosclerosis in ApoE-/- mice by suppressing the migration of vascular smooth muscle cell via PI3K-Akt-cofilin. [Abstract]

2025 Oct 20. PMID: 41114763
FASEB J

Periostin increased by mechanical stress upregulates interleukin-6 expression in the ligamentum flavum. [Abstract]

2023 Feb;37(2):e22726. PMID: 36583686
Lung

The Integrin Inhibitor Cilengitide and Bleomycin-Induced Pulmonary Fibrosis : Cilengitide and Bleomycin-Induced Pulmonary Fibrosis. [Abstract]

2020 Dec;198(6):947-955. PMID: 33146772
Cell Adh Migr

Fluid shear stress induces cell migration and invasion via activating autophagy in HepG2 cells. [Abstract]

2019 Dec;13(1):152-163. PMID: 30663937

Cilengitide purchased from MedChemExpress. Usage Cited in: Cell Adh Migr. 2019 Dec;13(1):152-163. [Abstract]

HepG2 cells are loaded with FSS at 1 dyn/cm2 for 0.5 h, with or without treatment of 0.5 μM Cli for 6 h prior to FSS application. Lysates are probed with antibodies as indicated.
Differentiation

Osteoclast-derived DEL1 promotes pathological bone formation in ankylosing spondylitis by regulating RUNX2 expression in osteoblasts. [Abstract]

2026 May-Jun:149:100962. PMID: 42128469
J Cell Physiol

FNDC5 inhibits malignant growth of human cervical cancer cells via restraining PI3K/AKT pathway. [Abstract]

2024 Jun;239(6):e31267. PMID: 38558303
Cell Biol Int

Protective effects of cilengitide on inflammation in chondrocytes under excessive mechanical stress. [Abstract]

2020 Apr;44(4):966-974. PMID: 31876323
Cancer Med

The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer. [Abstract]

2018 Feb;7(2):408-419. PMID: 29318780
Atheroscler Plus

Periostin contributes to the adventitial remodeling of atherosclerosis by activating adventitial fibroblasts. [Abstract]

2022 Oct 19:50:57-64. PMID: 36643802
J Integr Neurosci

Milk Fat Globule-EGF Factor 8 (MFGE8) Mitigates Cognitive Impairment in Rats with Sepsis-Associated Encephalopathy: An fMRI Study. [Abstract]

2024 Jul 25;23(7):140. PMID: 39082291
Biomed Res Int

Cilengitide Inhibits Neovascularization in a Rabbit Abdominal Aortic Plaque Model by Impairing the VEGF Signaling. [Abstract]

2021 Nov 30:2021:5954757. PMID: 34888383
PLoS One

Inhibition of Cellular Adhesion by Immunological Targeting of Osteopontin Neoepitopes Generated through Matrix Metalloproteinase and Thrombin Cleavage. [Abstract]

2016 Feb 3;11(2):e0148333. PMID: 26840958

Cilengitide purchased from MedChemExpress. Usage Cited in: PLoS One. 2016 Feb 3;11(2):e0148333. [Abstract]

Blockade of cellular adhesion of HEK 293 cells at 10 or 30 nM coated recombinant OPN forms with 1μM antagonistic integrin inhibitors. RGES (black bars) is used as a control peptide. Cilengitide (white bars) inhibits the integrins α_Vβ₃, α_Vβ₅, and α₅β₁. TR-14035 (hatched bars) inhibits the integrins α₄β₇ and α₄β₁. Depicted are the means ± SEM of 3 independent experiments. * indicate signif
PLoS One

A novel 2.5D culture platform to investigate the role of stiffness gradients on adhesion-independent cell migration. [Abstract]

2014 Oct 13;9(10):e110453. PMID: 25310593
J Mol Histol

Gingipains promote RANKL-induced osteoclastogenesis through the enhancement of integrin β3 in RAW264.7 cells. [Abstract]

2020 Apr;51(2):147-159. PMID: 32193744
J Oral Pathol Med

A Study on Regulating OSCC Cell Function by Blocking Integrin αvβ3 With Cilengitide. [Abstract]

2025 Aug;54(7):597-606. PMID: 40589419
Scand Cardiovasc J

Dual integrin αvβ3 and αvβ5 blockade attenuates cardiac dysfunction by reducing fibrosis in a rat model of doxorubicin-induced cardiomyopathy. [Abstract]

2021 Oct;55(5):287-296. PMID: 34296634
J Vis Exp

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes. [Abstract]

2025 May 23:(219). PMID: 40489409
bioRxiv

2026 Jun 1.
Res Sq

2026 May 3.
Universidad de Granada

2026.
Res Sq

2026 Feb 15.
bioRxiv

2026 Jan 05.
bioRxiv

2025 Sep 21.
SSRN

2025 Jul 7.
medRxiv

2025 Mar 23.
SSRN

2025 Feb 19.
bioRxiv

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK -driven lung cancer via concurrent integrin and MET signaling. [Abstract]

2024 Aug 28:2024.08.27.609975. PMID: 39253447
Patent

US20220378739A1.
Bioengineered

Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. [Abstract]

2022 Feb;13(2):4557-4572. PMID: 35142593
Research Square Preprint

2022 Jan.
bioRxiv

2020 Apr.
Patent

US20180263995A1.
Santa Clara University

2014 Jun 12.

Cilengitide purchased from MedChemExpress. Usage Cited in: Santa Clara University. 2014 Jun 12.

Cilengitide Photos: Pictures of migration through alginate with and without Cilengitide after four days. A) The view of the bottom of the untreated well, showing a healthy monolayer of U87s. B) The view of the cells suspended in alginate in the untreated well. A few of the multiple migrated cells within the image are marked with arrows. C) The view of the bottom of the Cilengitide treated well, showing very few, ill-attached U87s. D). The view of cells suspended in alginate in the Cilengitide-tr

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 44 mg/mL (74.75 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 35 mg/mL (59.46 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6988 mL

8.4939 mL

16.9877 mL

5 mM

0.3398 mL

1.6988 mL

3.3975 mL

10 mM

0.1699 mL

0.8494 mL

1.6988 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (169.88 mM); Clear solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (304 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kapp TG, et al. A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins. Scientific reports. 2017 Jan 11;7:39805. [Content Brief]

[2]. Pan X, et al. Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. Bioengineered. 2022 Feb;13(2):4557-4572. [Content Brief]

[3]. Hariharan S, et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007 Aug;18(8):1400-7. [Content Brief]

[4]. MacDonald TJ, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 20;26(6):919-24. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.6988 mL	8.4939 mL	16.9877 mL	42.4693 mL
	5 mM	0.3398 mL	1.6988 mL	3.3975 mL	8.4939 mL
	10 mM	0.1699 mL	0.8494 mL	1.6988 mL	4.2469 mL
	15 mM	0.1133 mL	0.5663 mL	1.1325 mL	2.8313 mL
	20 mM	0.0849 mL	0.4247 mL	0.8494 mL	2.1235 mL
	25 mM	0.0680 mL	0.3398 mL	0.6795 mL	1.6988 mL
	30 mM	0.0566 mL	0.2831 mL	0.5663 mL	1.4156 mL
	40 mM	0.0425 mL	0.2123 mL	0.4247 mL	1.0617 mL
	50 mM	0.0340 mL	0.1699 mL	0.3398 mL	0.8494 mL
DMSO	60 mM	0.0283 mL	0.1416 mL	0.2831 mL	0.7078 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Cilengitide

75 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Cilengitide

Publications Citing Use of MedChemExpress (MCE) Cilengitide

Alle Integrin Isoform-spezifische Produkte anzeigen

Alle TGF-β Receptor Isoform-spezifische Produkte anzeigen

Alle STAT Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle mTOR Isoform-spezifische Produkte anzeigen